ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 144

One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis

Tao Gu1, Derek Tang2, Gaurav Deshpande1, Debra F Eisenberg1 and David J. Harrison3, 1HealthCore, Wilmington, DE, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen Inc., Thousand Oaks, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic agents, Economics, rheumatoid arthritis (RA) and treatment options

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Switching a biologic treatment or escalating biologic doses are common approaches used upon biologic treatment failure. The objective of this study was to estimate the one-year costs after switching to another tumor necrosis factor inhibitor (TNFi) versus increasing the dose of the same TNFi among patients with rheumatoid arthritis (RA).

Methods: This was a retrospective cohort study using administrative data for individuals in the HealthCore Integrated Research Databases (HIRDSM). Initially, patients were included if they aged 18-63 with ≥1 claim for INF or ADA between Jul 1, 2009 and Jan 31, 2013, had ≥1 claim for RA during the 6 months prior to INF/ADA initiation, continuously enrolled between 6 months prior to and 12 months following INF/ADA initiation, and were not exposed to RA-related biologics 6 months prior to INF/ADA initiation or another condition for which RA-related biologics were approved to treat. Subsequently, INF/ADA patients switching to ADA/INF or ETN, or increasing the dose of the current drug in the subsequent year after treatment initiation were identified for further evaluation. Dose-escalation was defined for infliximab as having ≥120% of the expected infusions or an increase of ≥100 mg in dose; and for adalimumab as reaching a 40 mg weekly dose. Patients initiating ETN were not included in this analysis because dose-escalation in ETN has not been allowed per the approved US label. Patients who both dose-escalated and switched to a biologic of interest during the one-year follow-up were classified based on the first event. Costs were obtained from plan and patient paid amounts for biologic drug and administration and adjusted to 2013 dollar value.

Results: Of those who initiated ADA (n=1,437), 103 (7.2%) patients switched to INF/ETN and 103 (7.2%) patients increased their dose. Of those who initiated INF (n=539), 18 (3.3%) patients switched to ADA/ETN and 195 (36.2%) patients increased their dose. The average age was 48.6 (±10.2 [SD]) years and 74.7% were female. ADA initiators who dose-escalated on average incurred $8,843 higher costs compared with those who switched to another TNFi ($30,425 vs. $21,582, p<0.0001). INF initiators who dose-escalated on average incurred $9,022 higher costs compared with those who switched ($27,506 vs. $18,483, p=0.0007).

Conclusion: RA patients on ADA or INF incurred significantly higher costs when they dose escalated compared with switching to a new TNFi. The cost implications of increasing dose should be a consideration when making biologic treatment modifications in RA.


Disclosure: T. Gu, Amgen Inc., 5; D. Tang, Amgen Inc., 3,Amgen Inc., 1; G. Deshpande, Amgen Inc., 5; D. F. Eisenberg, Amgen Inc., 5; D. J. Harrison, Amgen Inc., 1,Amgen Inc., 3.

To cite this abstract in AMA style:

Gu T, Tang D, Deshpande G, Eisenberg DF, Harrison DJ. One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/one-year-costs-following-switching-versus-dose-escalation-among-prevalent-tumor-necrosis-factor-inhibitors-used-for-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/one-year-costs-following-switching-versus-dose-escalation-among-prevalent-tumor-necrosis-factor-inhibitors-used-for-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology